RATIONALE: Nicotine replacement is commonly used to treat tobacco use in heavy-drinking smokers. However, few studies have examined the effect of nicotine replacement on subjective and physiological responses to alcohol and alcohol drinking behavior. OBJECTIVE: The primary aim of this within-subject, double-blind study was to examine whether transdermal nicotine replacement (0 mg vs 21 mg/day) altered response to a low-dose priming drink and subsequent ad libitum drinking behavior. MATERIALS AND METHODS: Subjects (n=19) were non-treatment-seeking, non-dependent heavy drinkers who were daily smokers. Six hours after transdermal patch application, subjective and physiological responses to a priming drink [designed to raise blood alcohol levels (BALs) to 0.03 g/dl] were assessed. This was followed by a 2-h self-administration period where subjects could choose to consume up to eight additional drinks (each designed to raise BALs by 0.015 g/dl) or to receive monetary reinforcement for drinks not consumed. RESULTS: We found that 6 h after patch application, tobacco craving associated with withdrawal relief was decreased, and systolic blood pressure and heart rate were increased in the active patch condition compared to the placebo patch condition. Subjective intoxication in response to the priming drink was attenuated in the active nicotine patch condition compared to 6 h of nicotine deprivation (i.e., placebo patch). During the self-administration period, subjects had longer latencies to start drinking and consequently appeared to consume fewer drinks when administered the active patch compared to the placebo patch. CONCLUSIONS: In heavy drinkers, transdermal nicotine replacement compared to mild nicotine deprivation attenuated subjective and physiological alcohol responses and delayed the initiation of drinking.
RCT Entities:
RATIONALE: Nicotine replacement is commonly used to treat tobacco use in heavy-drinking smokers. However, few studies have examined the effect of nicotine replacement on subjective and physiological responses to alcohol and alcohol drinking behavior. OBJECTIVE: The primary aim of this within-subject, double-blind study was to examine whether transdermal nicotine replacement (0 mg vs 21 mg/day) altered response to a low-dose priming drink and subsequent ad libitum drinking behavior. MATERIALS AND METHODS: Subjects (n=19) were non-treatment-seeking, non-dependent heavy drinkers who were daily smokers. Six hours after transdermal patch application, subjective and physiological responses to a priming drink [designed to raise blood alcohol levels (BALs) to 0.03 g/dl] were assessed. This was followed by a 2-h self-administration period where subjects could choose to consume up to eight additional drinks (each designed to raise BALs by 0.015 g/dl) or to receive monetary reinforcement for drinks not consumed. RESULTS: We found that 6 h after patch application, tobacco craving associated with withdrawal relief was decreased, and systolic blood pressure and heart rate were increased in the active patch condition compared to the placebo patch condition. Subjective intoxication in response to the priming drink was attenuated in the active nicotine patch condition compared to 6 h of nicotine deprivation (i.e., placebo patch). During the self-administration period, subjects had longer latencies to start drinking and consequently appeared to consume fewer drinks when administered the active patch compared to the placebo patch. CONCLUSIONS: In heavy drinkers, transdermal nicotine replacement compared to mild nicotine deprivation attenuated subjective and physiological alcohol responses and delayed the initiation of drinking.
Authors: J B Daeppen; T L Smith; G P Danko; L Gordon; N A Landi; J I Nurnberger; K K Bucholz; E Raimo; M A Schuckit Journal: Alcohol Alcohol Date: 2000 Mar-Apr Impact factor: 2.826
Authors: R D Hurt; K M Eberman; I T Croghan; K P Offord; L J Davis; R M Morse; M A Palmen; B K Bruce Journal: Alcohol Clin Exp Res Date: 1994-08 Impact factor: 3.455
Authors: Kelly P Cosgrove; Irina Esterlis; Graeme F Mason; Frederic Bois; Stephanie S O'Malley; John H Krystal Journal: Neuropharmacology Date: 2011-01-27 Impact factor: 5.250
Authors: Jennifer G Plebani; Lara A Ray; Meghan E Morean; William R Corbin; James MacKillop; Michael Amlung; Andrea C King Journal: Alcohol Clin Exp Res Date: 2012-02-06 Impact factor: 3.455
Authors: Thomas M Piasecki; Phillip K Wood; Saul Shiffman; Kenneth J Sher; Andrew C Heath Journal: Psychopharmacology (Berl) Date: 2012-04-27 Impact factor: 4.530
Authors: Sarah S Dermody; Jennifer W Tidey; Rachel L Denlinger; Lauren R Pacek; Mustafa al'Absi; David J Drobes; Dorothy K Hatsukami; Ryan Vandrey; Eric C Donny Journal: Alcohol Clin Exp Res Date: 2016-02-25 Impact factor: 3.455
Authors: Timothy B Baker; K Michael Cummings; Dorothy K Hatsukami; C Anderson Johnson; Caryn Lerman; Raymond Niaura; Stephanie S O'Malley Journal: Nicotine Tob Res Date: 2009-07-24 Impact factor: 4.244
Authors: Stephanie S O'Malley; Suchitra Krishnan-Sarin; Sherry A McKee; Robert F Leeman; Ned L Cooney; Boris Meandzija; Ran Wu; Robert W Makuch Journal: Int J Neuropsychopharmacol Date: 2008-09-17 Impact factor: 5.176
Authors: Sherry A McKee; Kelly C Young-Wolff; Emily L R Harrison; K Michael Cummings; Ron Borland; Christopher W Kahler; Geoffrey T Fong; Andrew Hyland Journal: Alcohol Clin Exp Res Date: 2012-12-14 Impact factor: 3.455